---
schema_version: "secwatch.filing_event.v1"
accession: "0000917520-22-000021"
form_type: "8-K"
ticker: "IART"
cik: "0000917520"
company_name: "INTEGRA LIFESCIENCES HOLDINGS CORP"
filed_at: "2022-04-27T23:59:59+00:00"
generated_at: "2026-06-26T04:25:28.201224+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Integra LifeSciences Q1 adjusted EPS $0.74 beats prior year; raises FY organic growth guidance to 3.8%-5.2%

## Summary
- Revenues $376.6M (+4.6% reported, +5.6% organic); adjusted EPS $0.74 vs $0.69 Q1 2021; GAAP EPS $0.39 (down from $0.53, prior year included $42.9M divestiture gain).
- Codman Specialty Surgical rev $247.3M (org +5.0%); Tissue Technologies $129.3M (org +6.9%).
- FY 2022 organic growth guidance raised to 3.8%-5.2% (from 3.5%-5.0%); reported revenue reaffirmed $1.58B-$1.60B; adjusted EPS reaffirmed $3.27-$3.35.
- Board authorized new $225M share repurchase program (expires Dec 2024), replacing prior $225M program; completed $125M ASR in Q1.

## SEC filing metadata
- accession: 0000917520-22-000021
- form_type: 8-K
- ticker: IART
- cik: 0000917520
- company_name: INTEGRA LIFESCIENCES HOLDINGS CORP
- filed_at: 2022-04-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/917520/000091752022000021/0000917520-22-000021-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/917520/000091752022000021/iart-20220426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000917520-22-000021
- JSON: https://secwatch.observer/filing/0000917520-22-000021.json
- Plain text: https://secwatch.observer/filing/0000917520-22-000021.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.